RVMD Revolution Medicines Inc

Price (delayed)

$29.99

Market cap

$2.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.07

Enterprise value

$2.04B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities ...

Highlights
The debt has contracted by 4.3% YoY
The company's equity has surged by 90% YoY but it fell by 5% QoQ
RVMD's quick ratio has surged by 87% year-on-year but it is down by 9% since the previous quarter
Revolution Medicines's net income has plunged by 93% YoY and by 14% from the previous quarter
The revenue has declined by 13% year-on-year and by 3.2% since the previous quarter

Key stats

What are the main financial stats of RVMD
Market
Shares outstanding
73.58M
Market cap
$2.21B
Enterprise value
$2.04B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.22
Price to sales (P/S)
54.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.76
Earnings
Revenue
$40.24M
EBIT
-$142.5M
EBITDA
-$135.65M
Free cash flow
-$130.13M
Per share
EPS
-$2.07
Free cash flow per share
-$1.77
Book value per share
$9.33
Revenue per share
$0.55
TBVPS
$9.52
Balance sheet
Total assets
$774.05M
Total liabilities
$89.04M
Debt
$32.49M
Equity
$685.01M
Working capital
$615.21M
Liquidity
Debt to equity
0.05
Current ratio
14.43
Quick ratio
14.28
Net debt/EBITDA
1.21
Margins
EBITDA margin
-337.1%
Gross margin
100%
Net margin
-355.1%
Operating margin
-356.8%
Efficiency
Return on assets
-20.8%
Return on equity
-23.9%
Return on invested capital
-34%
Return on capital employed
-19.6%
Return on sales
-354.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
0.71%
1 week
-6.43%
1 month
5.19%
1 year
-11.46%
YTD
-24.25%
QTD
-5.51%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$40.24M
Gross profit
$40.24M
Operating income
-$143.56M
Net income
-$142.9M
Gross margin
100%
Net margin
-355.1%
The net margin has plunged by 121% YoY and by 17% from the previous quarter
Revolution Medicines's operating margin has plunged by 100% YoY and by 17% from the previous quarter
Revolution Medicines's net income has plunged by 93% YoY and by 14% from the previous quarter
RVMD's operating income has dropped by 75% year-on-year and by 13% since the previous quarter

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
3.22
P/S
54.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.76
The EPS has surged by 85% year-on-year but it has declined by 7% since the previous quarter
The company's equity has surged by 90% YoY but it fell by 5% QoQ
The P/B is 29% lower than the last 4 quarters average of 4.5
The revenue has declined by 13% year-on-year and by 3.2% since the previous quarter
The stock's price to sales (P/S) is 7% less than its last 4 quarters average of 58.7

Efficiency

How efficient is Revolution Medicines business performance
The return on sales has dropped by 106% year-on-year and by 17% since the previous quarter
Revolution Medicines's return on equity has surged by 68% YoY and by 2% QoQ
RVMD's ROIC is up by 26% year-on-year but it is down by 3.7% since the previous quarter
RVMD's ROA is up by 16% YoY

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
RVMD's quick ratio has surged by 87% year-on-year but it is down by 9% since the previous quarter
Revolution Medicines's current ratio has soared by 85% YoY but it has decreased by 9% from the previous quarter
The debt is 95% less than the equity
The company's equity has surged by 90% YoY but it fell by 5% QoQ
The debt to equity has contracted by 44% YoY but it has grown by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.